# The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

> **NCT06976619** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Type 1 Diabetes
- Type 2 Diabetes

## Interventions

- **DRUG:** Liraglutide Pen Injector
- **OTHER:** Saline Injections

## Key facts

- **NCT ID:** NCT06976619
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-03
- **Primary completion:** 2028-10-30
- **Final completion:** 2029-03-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06976619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06976619, "The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06976619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*